MedPath

Communication in Breast Cancer Care

Not Applicable
Completed
Conditions
Communication
Breast Cancer
Quality of Life
Interventions
Behavioral: Communciation intervention
Registration Number
NCT05390723
Lead Sponsor
Leiden University
Brief Summary

The investigators will create 4 information-video's about chemotherapy side-effects in curative breast cancer care. The communication is manipulated in the four videos. Participants will watch the video before the first chemotherapy and complete questionnaires before and after viewing the video and after chemotherapy 1,2 and 4. (The investigators cannot yet reveal the manipulation as it would influence the participants)

Detailed Description

NA, the investigators cannot yet reveal the manipulation as it would influence the participants.

Recruitment & Eligibility

Status
COMPLETED
Sex
Female
Target Recruitment
27
Inclusion Criteria
  • Adult (>18 years old) female breast cancer patients
  • Chemo-naïve patients
  • Scheduled in for curative neo-adjuvant chemotherapy: Four courses of AC chemotherapy (all combinations of AC + other chemotherapy courses are eligible)
  • Cognitively able to fill out an online questionnaire
  • Having internet access
  • Sufficient command of the Dutch language
  • pre-chemo no previous treatment or pre-chemo breast-conserving surgery and radiotherapy (WLE patients)
Exclusion Criteria
  • NA

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
video 3Communciation interventionthe investigators cannot yet reveal the specific communication that will be manipulate, as this might influence participant outcomes.
video 4Communciation interventionthe investigators cannot yet reveal the specific communication that will be manipulate, as this might influence participant outcomes.
video 1Communciation interventionThe investigators cannot yet reveal the specific communication that will be manipulate, as this might influence participant outcomes.
video 2Communciation interventionThe investigators cannot yet reveal the specific communication that will be manipulate, as this might influence participant outcomes.
Primary Outcome Measures
NameTimeMethod
AnxietyDay 0 (day before chemo 1), day 7-10 (week after chemo 1), day 21-23 (week after chemo 2), and day 52-54 (10 days after chemo 4). (This might be subject to change in cases where the days of the chemo therapy are changed

measuring the change in anxiety measured using a shortened version of the State-Trait Anxiety Inventory (STAI-S)

Secondary Outcome Measures
NameTimeMethod
information needsDay 0 (day before chemo 1)

coping infromation needs ( 2 questions)

psychological outcomesDay 0 (day before chemo 1), day 7-10 (week after chemo 1), day 21-23 (week after chemo 2), and day 52-54 (10 days after chemo 4). (This might be subject to change in cases where the days of the chemo therapy are changed

measuring the change in psychological outcomes communication satisfaction, trust, self-efficacy, distress (4 questions)

medical outcomesday 54 (12 days after chemo 4). (This might be subject to change in cases where the days of the chemo therapy are changed

use of co-medication (1 question)

socio-demographicsDay 0 (day before chemo 1)

measuring the change in age, SES, education age, SES, education (7 questions)

anxietytrait: Day 0 (day before chemo 1), current: Day 0 (day before chemo 1), day 7-10 (week after chemo 1), day 21-23 (week after chemo 2), and dday 52-54 (10 days after chemo 4).

measuring the change in anxiety trait (20 questions) and current anxiety (1 question)

side effects (expected and experienced)expected: Day 0 (day before chemo 1); experienced: day 7-10 (week after chemo 1), day 21-23 (week after chemo 2), and day 52-54 (10 days after chemo 4). (This might be subject to change in cases where the days of the chemo therapy are changed

measuring the change in side effects side effects (expected) (31 questions): probability, intensity, coping, and compliance intention side effects (experienced)(21 questions): intensity, number, coping, compliance intention

Trial Locations

Locations (1)

Antoni van Leeuwenhoek

🇳🇱

Amsterdam, North Holland, Netherlands

© Copyright 2025. All Rights Reserved by MedPath